MY112413A - Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals - Google Patents
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticalsInfo
- Publication number
- MY112413A MY112413A MYPI94002894A MYPI19942894A MY112413A MY 112413 A MY112413 A MY 112413A MY PI94002894 A MYPI94002894 A MY PI94002894A MY PI19942894 A MYPI19942894 A MY PI19942894A MY 112413 A MY112413 A MY 112413A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceuticals
- preparation
- substituted heterocyclic
- heterocyclic carboxamides
- carboxamides
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- -1 heterocyclic carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 abstract 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 abstract 1
- 230000036570 collagen biosynthesis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA I,FORMULATO A PROCESS FOR THEIR PREPARATION AND TO THEIR USE AS PHARMACEUTICALS. THE COMPOUNDS ARE EMPLOYED, IN PARTICULAR, FOR INHIBITING COLLAGEN BIOSYNTHESIS AND AS INHIBITORS OF PROLYL HYDROXYLASE AND AS FIBROSUPPRESSIVEAGENTS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4337271A DE4337271A1 (en) | 1993-11-02 | 1993-11-02 | ubstd. heterocyclic carboxylic acid amides and their prepn. |
| DE19944410881 DE4410881A1 (en) | 1994-03-29 | 1994-03-29 | Substd. heterocyclic carboxylic acid amides and their prepn. |
| DE19944433928 DE4433928A1 (en) | 1994-09-23 | 1994-09-23 | Substd. heterocyclic carboxylic acid amides and their prepn. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY112413A true MY112413A (en) | 2001-06-30 |
Family
ID=27205714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI94002894A MY112413A (en) | 1993-11-02 | 1994-10-31 | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0650961B1 (en) |
| JP (1) | JPH07228571A (en) |
| KR (1) | KR950014072A (en) |
| CN (1) | CN1107145A (en) |
| AT (1) | ATE149486T1 (en) |
| AU (1) | AU676775B2 (en) |
| CA (1) | CA2134866A1 (en) |
| CY (1) | CY2120B1 (en) |
| CZ (1) | CZ289356B6 (en) |
| DE (1) | DE59401924D1 (en) |
| DK (1) | DK0650961T3 (en) |
| ES (1) | ES2101421T3 (en) |
| GR (1) | GR3023174T3 (en) |
| IL (1) | IL111454A (en) |
| MY (1) | MY112413A (en) |
| NO (1) | NO301880B1 (en) |
| NZ (1) | NZ264821A (en) |
| PL (1) | PL179794B1 (en) |
| TW (1) | TW399046B (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides |
| DE19746287A1 (en) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
| FR2803592A1 (en) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME |
| DE10123587B4 (en) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamide derivatives and their use as pharmaceuticals |
| DE10123573B4 (en) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamide derivatives and their use as pharmaceuticals |
| DE50206476D1 (en) | 2001-05-08 | 2006-05-24 | Schering Ag | CYANOANTHRANYLAMID DERIVATIVES AND THEIR USE AS DRUGS |
| CN102526045A (en) | 2001-12-06 | 2012-07-04 | 法布罗根股份有限公司 | Methods of increasing endogenous erythropoietin EPO |
| EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
| CN101664553B (en) * | 2001-12-06 | 2013-08-21 | 法布罗根股份有限公司 | Stabilization of hypoxia inducible factor (HIF) alpha |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| KR100932169B1 (en) | 2003-06-06 | 2009-12-16 | 피브로겐, 인크. | Nitrogen-containing heteroaryl compounds and their use in the increase of endogenous erythropoiesis |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| CN101166745A (en) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | Novel thienopyridine compounds, and methods of use thereof |
| US20060276477A1 (en) * | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| ATE470439T1 (en) | 2005-06-15 | 2010-06-15 | Fibrogen Inc | USE OF HIF 1ALFA MODULATORS TO TREAT CANCER |
| WO2007090068A2 (en) | 2006-01-27 | 2007-08-09 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| EP2016078B1 (en) * | 2006-04-04 | 2016-06-15 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| NZ601730A (en) * | 2006-06-26 | 2014-04-30 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
| ES2360929T3 (en) * | 2007-09-20 | 2011-06-10 | Amgen Inc. | ACID DERIVATIVES 1- (4- (4-BENCILBENZAMIDO) -BENCIL) AZETIDIN-3-CARBOXYL AND RELATED COMPOUNDS AS MODULATORS OF THE S1P RECEPTOR FOR THE TREATMENT OF IMMUNE DISORDERS. |
| CN102272117B (en) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | Benzothiopyran derivatives as HIF hydroxylase inhibitors |
| KR101007674B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | High speed spray gun and coating device with auxiliary cap |
| KR101007675B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | Plasma spray gun with auxiliary cap and plasma spray system using the same |
| NO2686520T3 (en) | 2011-06-06 | 2018-03-17 | ||
| SG11201405574UA (en) | 2012-03-09 | 2014-10-30 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| KR101629767B1 (en) | 2012-07-04 | 2016-06-13 | 아구로카네쇼 가부시키가이샤 | 2-Aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
| US9340511B2 (en) | 2012-07-16 | 2016-05-17 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| US9115085B2 (en) | 2012-07-16 | 2015-08-25 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| WO2014116849A1 (en) | 2013-01-24 | 2014-07-31 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| IL296484B2 (en) | 2013-06-06 | 2025-03-01 | Fibrogen Inc | Pharmaceutical formulations of a hif hydroxylase inhibitor |
| SMT202400092T1 (en) | 2013-06-13 | 2024-05-14 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| EP3578546A1 (en) | 2013-11-15 | 2019-12-11 | Akebia Therapeutics Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| HK1247201A1 (en) | 2015-01-23 | 2018-09-21 | 阿克比治疗有限公司 | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| CN106146395B (en) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3- hydroxypyridine compound, preparation method and its pharmaceutical applications |
| PL3277270T3 (en) | 2015-04-01 | 2022-02-14 | Akebia Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF ISKNIA |
| CA3097219A1 (en) | 2018-05-09 | 2019-11-14 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| PL3808747T3 (en) * | 2018-09-13 | 2025-03-17 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| US12612367B2 (en) | 2019-12-10 | 2026-04-28 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4015255A1 (en) | 1990-05-12 | 1991-11-14 | Hoechst Ag | OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE |
| EP0541042A1 (en) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use |
| JPH07504654A (en) * | 1992-03-11 | 1995-05-25 | ナルヘックス リミテッド | Amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
-
1994
- 1994-10-27 AT AT94117018T patent/ATE149486T1/en not_active IP Right Cessation
- 1994-10-27 EP EP94117018A patent/EP0650961B1/en not_active Expired - Lifetime
- 1994-10-27 DE DE59401924T patent/DE59401924D1/en not_active Expired - Fee Related
- 1994-10-27 DK DK94117018.5T patent/DK0650961T3/en active
- 1994-10-27 ES ES94117018T patent/ES2101421T3/en not_active Expired - Lifetime
- 1994-10-28 PL PL94305646A patent/PL179794B1/en unknown
- 1994-10-30 IL IL11145494A patent/IL111454A/en not_active IP Right Cessation
- 1994-10-31 MY MYPI94002894A patent/MY112413A/en unknown
- 1994-10-31 NZ NZ264821A patent/NZ264821A/en unknown
- 1994-10-31 AU AU77564/94A patent/AU676775B2/en not_active Ceased
- 1994-11-01 CA CA002134866A patent/CA2134866A1/en not_active Abandoned
- 1994-11-01 CZ CZ19942683A patent/CZ289356B6/en not_active IP Right Cessation
- 1994-11-01 NO NO944162A patent/NO301880B1/en not_active IP Right Cessation
- 1994-11-02 CN CN94117623A patent/CN1107145A/en active Pending
- 1994-11-02 JP JP6292032A patent/JPH07228571A/en not_active Abandoned
- 1994-11-02 KR KR1019940028871A patent/KR950014072A/en not_active Ceased
- 1994-12-05 TW TW083111257A patent/TW399046B/en not_active IP Right Cessation
-
1997
- 1997-04-18 GR GR970400831T patent/GR3023174T3/en unknown
-
1998
- 1998-09-29 CY CY9800039A patent/CY2120B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL305646A1 (en) | 1995-05-15 |
| IL111454A0 (en) | 1994-12-29 |
| AU7756494A (en) | 1995-05-18 |
| CA2134866A1 (en) | 1995-05-03 |
| KR950014072A (en) | 1995-06-15 |
| CZ289356B6 (en) | 2002-01-16 |
| HK1006711A1 (en) | 1999-03-12 |
| ES2101421T3 (en) | 1997-07-01 |
| CZ268394A3 (en) | 1995-05-17 |
| IL111454A (en) | 2001-08-08 |
| NZ264821A (en) | 1997-02-24 |
| EP0650961B1 (en) | 1997-03-05 |
| NO301880B1 (en) | 1997-12-22 |
| PL179794B1 (en) | 2000-10-31 |
| NO944162L (en) | 1995-05-03 |
| TW399046B (en) | 2000-07-21 |
| AU676775B2 (en) | 1997-03-20 |
| NO944162D0 (en) | 1994-11-01 |
| CN1107145A (en) | 1995-08-23 |
| JPH07228571A (en) | 1995-08-29 |
| CY2120B1 (en) | 2002-04-26 |
| ATE149486T1 (en) | 1997-03-15 |
| DE59401924D1 (en) | 1997-04-10 |
| GR3023174T3 (en) | 1997-07-30 |
| EP0650961A1 (en) | 1995-05-03 |
| DK0650961T3 (en) | 1997-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL111454A0 (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
| MY131657A (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
| PH31264A (en) | Substituted heterocyclic carboxamide esters, and their use as pharmaceuticals. | |
| GEP20033028B (en) | Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof | |
| MY133647A (en) | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | |
| IL114315A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV | |
| CA2107105A1 (en) | Heterocyclic-cyclic amine derivatives | |
| AU5488498A (en) | Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them | |
| PL327275A1 (en) | Matalproteinase inhibitors, pharmaceutic compositions containing them and their application as well as method of and substrates for obtaining them | |
| AU2364600A (en) | Heteroroaromatic amides as inhibitor of factor xa | |
| AU4712396A (en) | Chiral methylphenyloxazolidinones | |
| AU5875498A (en) | Substituted derivatives of benzosulphonamides as inhibitors of the enzyme cyclo oxygenase ii | |
| MX9800408A (en) | Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts. | |
| AU2364000A (en) | Heterocyclic amides as inhibitors of factor xa | |
| NO984740L (en) | Isatin derivatives such as acetylcholinesterase inhibitors and analgesics | |
| ES8707538A1 (en) | 11-Substituted 5H,11H-pyrrolo[2,1-c][1,4]benzoxazepines, a process for their preparation and their use in medicaments. | |
| WO2002014313A3 (en) | Novel beta-amyloid inhibitors, method for producing the same and the use thereof as medicaments | |
| CA2218663A1 (en) | Benzisoxazole and indazole derivatives as antipsychotic agents | |
| HUP0202988A3 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0103020A3 (en) | Heterocyclic derivatives as fkbp inhibitors, process for their preparation, their intermediates and pharmaceutical compositions containing them | |
| DE69801811D1 (en) | ALKYKENDIAMIN DI- OR TRI-ACETIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN COSMETIC COMPOSITIONS | |
| MY112414A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals | |
| AU650511B2 (en) | 2,4- and 2,5-bistetrazolypyridines, a process for the preparation thereof and the use thereof as pharmaceuticals | |
| ATE228359T1 (en) | INHIBITION OF LEUKOTRIE BIOSYNTHESIS USING UREA DERIVATIVES | |
| MX9710530A (en) | BENZO[g]QUINOLINE DERIVATIVES. |